Treatment Action Group did an analysis of ongoing research in the pipeline for Gonorrhea, Chlamydia, and Syphilis. This study identified that the current toolbox for addressing gonorrhea, chlamydia, and syphilis is inadequate.
To read the full report, click here.
Some notable progress has emerged in the research pipelines for the treatment and prevention of gonorrhea, chlamydia, and syphilis. Efforts to develop novel treatment options for gonorrhea have been particularly productive; there is also some movement in prevention research with promising findings for doxycycline as PrEP and PEP for chlamydia and syphilis, as well as increased funding for vaccine research across all three diseases. Additionally, our glimpse into some promising developments in the area of rapid POC diagnostics may assist with better detection and early treatment of bacterial STIs.
Based upon this review, TAG makes the following recommendations for community advocates and other key stakeholders in the worsening gonorrhea, chlamydia, and syphilis epidemics: